Tele: 561.316.3330
Breaking Medical Device News

Tuesday, October 19, 2021

HomeMEDICAL DEVICESFirst Vascular Access Company to Guarantee Hospitals Will See Cost Savings and...

First Vascular Access Company to Guarantee Hospitals Will See Cost Savings and Improved Overall Patient Outcomes

MARKET REPORTS

Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets – ResearchAndMarkets.com

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts – ResearchAndMarkets.com

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

Today Access Scientific, LLC, manufacturer of POWERWAND™ midline and extended dwell catheters, reports they are now providing hospitals a guarantee that they will be able to reduce their central-line associated bloodstream infections (CLABSIs). The company also guarantees that hospitals will be able to reduce their use of one of the primary contributors to CLABSI — peripherally inserted central catheters (PICCs) — by a mimimum of 25%.

The guarantee aligns with the national initiative to reduce hospital acquired conditions (HACs) and stop putting patients through unnecessary risk. In the U.S., approximately 48 percent of ICU patients have indwelling central venous catheters, accounting for 15 million central line days per year1. Assuming an average CLABSI rate of 5.3 per 1000 catheter-days, as many as 79,500 CLABSIs are experienced each year in ICUs1.

CLABSI are an acute problem within healthcare, and Access Scientific guarantees it can help make a difference. At an average cost of $48,108 per infection2, this non-reimbursable HAC results in over $3 billion in related costs per year to the American healthcare system. Even more troubling, because CLABSIs have the highest mortality rate of any HAC at 18%1, as many as 14,000 U.S. patients die annually from CLABSI.

POWERWAND post-market surveillance demonstrates a reduction of CLABSIs by at least 10% when implemented as a part of an evidence-based, vascular-access-device patient program. Expanding these results nationally, the financial and clinical impact would be momentous, resulting in over 1,400 lives saved and $382.5 million in annual cost savings.

or patient stays longer than three days, the POWERWAND catheter is supported by overwhelming clinical evidence demonstrating a high completion of IV therapy. This performance allows hospitals to confidently utilize the POWERWAND as a solution for patients who previously would have been subjected to receiving a PICC.

When implementing an evidence-based VAD patient algorithm, hospitals have shown the ability to substantially reduce their PICC usage with the POWERWAND. This reduction in the overall use of central catheters has a direct impact on the total number of CLABSIs. Tables 1 and 2 demonstrate the proven outcomes associated with the POWERWAND through fewer CLABSIs and reduced overall PICC usage.

Table 1. PICC Reduction

Lead Author

Institution(s)

Scientific Journal

PICC Reduction

Moureau

Hospital 1 – Level-1 trauma center, 400-bed Magnet recognized teaching hospital

JAVA, 2015

58%

Pathak

Richmond University Medical Center

Infectious Diseases in Clinical Practice, 2015

37%

Hochman

NYU Langone

Vizient National Conference, 2018

69%

DeVries

Methodist Hospitals

AJIC, 2019

35%

Table 2. CLABSI Reduction

Lead Author

Institution

Scientific Journal

CLABSI Reduction

Moureau

Hospital 1 – Level-1 trauma center

Hospital 2 – 215 bed not-for-profit hospital

JAVA, 2015

Hospital 1 – 88%

Hospital 2 – 100%

Pathak

Richmond University Medical Center

Infectious Diseases in Clinical Practice, 2015

100%

Hochman

NYU Langone

Vizient National Conference, 2018

100%

DeVries

Methodist Hospitals

AJIC, 2019

Estimated 10 CLABSIs avoided

The above outcomes result in significant savings both in purchasing ($90 per POWERWAND vs cost of a PICC3) and clinical costs ($48,108 per CLABSI1).

As further incentive to healthcare providers, Access Scientific will provide meaningful compensation in the event a hospital fails to reach their targets.

This unique guarantee is based on the superior performance of the POWERWAND. Unlike other devices in its class, the POWERWAND is supported by nine peer reviewed publications and nine scientific posters. These post-market studies have documented reduced overall CLABSIs and significant cost savings when using the POWERWAND, a device that has recorded over 36,000 catheter-days with zero bloodstream infections. These results are the backbone of the risk share guarantee. They also underpin Access Scientific’s confidence to be a valuable partner for healthcare providers that are looking to improve overall patient outcomes and reduce costs. The risk share guarantee was designed to support value based decisions and truly make a difference.

spot_img

DON'T MISS

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy